Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byJose A Rauh-Hain

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial collects information about factors that affect communication of genetic test results, decision-making, and access to genetic testing in women with hereditary gynecological cancers. Studying individuals who are positive for a genetic mutation and immediate biological family members (including a parent, full-sibling, or child) may help identify cancer genes and other persons at risk.

Research Team

Jose A Rauh-Hain

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

Inclusion Criteria

STEP 1 (PROBANDS): Has completed genetic counseling, with pedigree available in the medical record (LBJ)

STEP 1 (PROBANDS): Diagnosed with female-breast, ovarian, fallopian tube, primary peritoneal, endometrial cancer on or after January 1, 2014

STEP 1 (PROBANDS): Has a confirmed deleterious or suspected deleterious (pathogenic) variant in a hereditary gynecologic or breast cancer predisposition gene (including BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, BRIP1, PALB2, RAD51C, RAD51D, STK11, DICER1, SMARCA4, ATM, CHEK2, PTEN, TP53, CDH1, BARD1)

See 7 more

Treatment Details

Interventions

Interview (Behavioural Intervention)
Questionnaire Administration (Behavioural Intervention)
Survey Administration (Behavioural Intervention)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Observational (interview, survey)Experimental Treatment3 Interventions

STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes. STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes.